AUTHORS
Chengcheng Fu, MD,PhD, Wanhong Zhao, MD2, Baijun Fang, PhD3, Haiping Yang, MD4, Liping Su, MD5, Zhongjun Xia, MD, PhD6, Wenbin Qian, MD7, Chunyan Sun, MD8, Yafei Wang, MD9, Ming Lv, PhD10, Shiwei Miao, PhD11, Ziming Liu12, Jing Yang, PhD13, Depei Wu, MD, PhD14, Wenming Chen, MD15
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China
2 The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
5 Shanxi Provincial Cancer Hospital, Taiyuan, China
6 Sun Yat-sen University Cancer Center, Guangzhou, China
7 The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
8 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
10 Hangzhou Sumgen Biotech Co., Ltd., Hangzhou, China
11 Hangzhou Sumgen Biotech Co., Ltd., Hangzhou, China
12 Hangzhou Sumgen Biotech Co., Ltd., Beijing, China
13 Hangzhou Sumgen Biotech Co., Ltd., Beijing, China
14 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China
15 Beijing Chao-Yang Hospital of Capital Medical University, Beijing, China
ABSTRACT
Background: Anti-CD38 monoclonal antibody-based regimens have revolutionized the treatment landscape for multiple myeloma (MM). Sanritatug is a novel humanized IgG1-κ anti-CD38 monoclonal antibody targeting an epitope distinct from daratumumab. Preclinical data demonstrate that sanritatug exhibits stronger antibody-dependent cellular cytotoxicity (ADCC) and no complement-dependent cytotoxicity (CDC) activity compared to daratumumab. A phase 1 monotherapy trial in patients (pts) with relapsed/refractory (R/R) MM confirmed that single-agent sanritatug was well tolerated, with manageable hematologic toxicities and a low incidence of infusion-related reactions (IRRs). The 8 mg/kg dose yielded sustained target saturation and a promising efficacy signal. Preclinical studies have further validated that the combination of sanritatug and pomalidomide exerts potent synergistic antitumor activity. Supported by these robust preclinical and clinical findings, this two-stage phase 3 trial (NCT06508983) was designed to evaluate the safety and efficacy of sanritatug in combination with pomalidomide plus dexamethasone (Pd) in Chinese pts with R/R MM. Herein, we present the preliminary outcomes of stage 1 dose-exploration part of this study.
Methods: This phase 3 trial adopted a two-stage design: open-label stage 1 dose exploration (primary endpoint: safety) and double-blind, 2:1 randomized stage 2 (primary endpoint: progression-free survival [PFS]). Eligible adults with R/R MM had ≥1 prior lenalidomide- and proteasome inhibitor (PI)-containing regimen plus confirmed disease relapse or refractoriness. Stage 1 comprised a 3+3 dose-finding and expansion part for sanritatug initiated at 8 mg/kg, plus Pd on a 28-day cycle. Sanritatug was infused weekly for the first two cycles, then biweekly. Oral pomalidomide 4 mg was administered days 1–21 per cycle, with weekly 40 mg dexamethasone. Dose-limiting toxicities (DLTs) were assessed in Cycle 1; ≥2 DLTs among six evaluable pts at 8 mg/kg would trigger de-escalation to 4 mg/kg sanritatug. Cohorts with acceptable safety were expanded to at least 15 pts. Treatment continued until disease progression or unmanageable toxicity. All DLTs and adverse events (AEs) were graded by NCI-CTCAE v5.0, and responses were evaluated per 2016 IMWG criteria. A Safety Monitoring Committee (SMC) reviewed pooled safety and efficacy data to authorize progression to randomized stage 2.
Results: As of April 1, 2026, a total of 34 R/R MM pts were enrolled in stage 1 (3 in the 3+3 dose-finding part and 31 in the dose expansion part) and all received sanritatug 8 mg/kg combined with Pd. The median age was 61.5 years (range: 42–74). Pts received a median of 2 prior lines of therapy (range: 1–6). All pts had prior exposure to both PIs and lenalidomide, with 76.5% lenalidomide-refractory and 70.6% PI-refractory. At baseline 35.3% pts had high-risk cytogenetics. No DLTs, AEs of special interest (AESI, ≥Grade 3 IRR), treatment-discontinuing AEs or fatal AEs were reported. IRRs were mild (14.7%, grade 1–2). Common grade ≥3 AEs (≥10%) included neutropenia (94.1%), leukopenia (88.2%), lymphopenia (50.0%), thrombocytopenia (50.0%), lung infections (26.5%), anemia (20.6%), upper respiratory tract infection (17.6%), and hypertriglyceridemia (14.7%). Grade 4 neutropenia and thrombocytopenia occurred in 61.8% and 5.9% pts, respectively. Grade ≥3 hematologic AEs were manageable with supportive care and dose adjustments. Serious adverse events (SAEs) were reported in 35.3% of pts; lung infection (17.6%) was the only SAE observed in more than one patient. Clinical benefits continued to deepen with extended treatment at the current data cut-off. Among 32 efficacy-evaluable pts, overall response rate (ORR, partial response [PR] + very good partial response [VGPR] + complete response [CR] + stringent CR [sCR]) was 78.1% (95% CI: 60.0%–90.7%). The ≥VGPR rate was 53.1%, including 7 VGPRs (21.9%), 3 CRs (9.4%) and 7 sCRs (21.9%). At a median follow-up of 12.0 months, median duration of response (DoR) and median PFS were not reached. The 12-month DoR rate was 67.9% (95% CI: 40.7%–84.7%), and the 12-month PFS rate was 61.8% (95% CI: 40.9%–77.2%).
Conclusion: Sanritatug at 8 mg/kg plus Pd demonstrated predictable, manageable safety and favorable tolerability in R/R MM pts. The combination induced durable responses that deepened with prolonged treatment. Randomized double-blind stage 2 is ongoing for further efficacy validation.
DISCLOSURES
Chengcheng Fu, MD,PhD: No relevant conflicts of interest to declare.